MK2 is a therapeutic target for high-risk multiple myeloma
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2017.182121
Abstract: Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by heterogeneous genetic diversity. Although the development of proteasome inhibitors and immumodulatory drugs combined with autologous stem cell transplantation (ASCT) have achieved advanced improvement for… read more here.
Keywords: high risk; mk2; multiple myeloma; expression ... See more keywords